Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 214

Sort by

Sort Order Select

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Allogeneic hematopoietic cell transplantation risk stratification and eligibility using race-neutral versus race-specific pulmonary equations

Felipe Soto, Gordon Smilnak, Adarsh Suresh, Caroline Sublett, Guang-Shing Cheng, Jeffrey Sturek, Gabriela Rondon, Amin Alousi, Hemang Yadav, Ajay Sheshadri

Blood (2025) 146 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2025-4306

Published: 2025

Journal Articles

Prospective observational cohort study to collect granular social determinants of health data for hematopoietic cell transplant patients

Warren Fingrut, KaNoisha Codrington, Denai Milton, Ligny Hunter, Ricky Garcia, Charles Martinez, Gabriela Rondon, Christopher Flowers, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 6163.

https://doi.org/10.1182/blood-2025-6163

Published: 2025

Journal Articles

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

Yu-Hsiang Chen, Timothy Bi, Minhang Xu, Jaehyun Lee, Wesley Lu, Mengchuan Zhuang, Alejandro Marinos Velarde, Hui Yang, Gheath Alatrash, Gabriela Rondon, Elizabeth Shpall, Fatima Jelloul, Frances Cervoni-Curet, Celine Kerros, Priya Koppikar, Jeffrey Molldrem, Guillermo Garcia-Manero, Ankit Patel, Pavan Bachireddy

Blood (2025) 146 (Supplement 1): 674.

https://doi.org/10.1182/blood-2025-674

Published: 2025

Journal Articles

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Blood (2025) 146 (Supplement 1): 592.

https://doi.org/10.1182/blood-2025-592

Published: 2025

Journal Articles

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Blood (2025) 146 (Supplement 1): 6058.

https://doi.org/10.1182/blood-2025-6058

Published: 2025

Journal Articles

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Issa Khouri, Susan Wu, Fadi Haddad, Denai Milton, Tapan Kadia, Nicholas Short, Koji Sasaki, Jin Im, David Marin, Rohtesh Mehta, Gabriela Rondon, Hind Rafei, Jeremy Ramdial, Guillermo Garcia-Manero, Dan Li, Alison Gulbis, Bouthaina Dabaja, Elias Jabbour, Qing Ma

Blood (2025) 146 (Supplement 1): 6022.

https://doi.org/10.1182/blood-2025-6022

Published: 2025

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2025-5994

Published: 2025

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Blood (2024) 144 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2024-203864

Published: 2024

Journal Articles

Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

Warren B Fingrut, KaNoisha Codrington, Ligny Hunter, Ricky Garcia, Charles Martinez, Gabriela Rondon, Denái R. Milton, Christopher R. Flowers, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 3573.1.

https://doi.org/10.1182/blood-2024-202666

Published: 2024

Journal Articles

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Blood (2023) 142 (Supplement 1): 656.

https://doi.org/10.1182/blood-2023-178150

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Blood (2023) 142 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2023-179962

Published: 2023

Journal Articles

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2023) 142 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2023-181031

Published: 2023

Journal Articles

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4972.

https://doi.org/10.1182/blood-2023-189844

Published: 2023

Journal Articles

Clinical Factors Associated with Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation

Naveen Subramanian, Katherine Klein, Danielle Guffey, Partow Kebriaei, Gabriela Rondon, Elizabeth J. Shpall, Jeff Jin, Elliana Young, Ang Li, Cristhiam M. Rojas Hernandez

Blood (2023) 142 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2023-182490

Published: 2023

Journal Articles

The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant

Rima M. Saliba, Curtis Marcoux, Amin Alousi, Gabriela Rondon, Julianne Chen, May Daher, MD, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2023) 142 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2023-188108

Published: 2023

Journal Articles

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Blood (2023) 142 (Supplement 1): 233.

https://doi.org/10.1182/blood-2023-181880

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Optimizing essential, complex hematologic care for patients living with disabilities

Allogeneic hematopoietic cell transplantation risk stratification and eligibility using race-neutral versus race-specific pulmonary equations

Prospective observational cohort study to collect granular social determinants of health data for hematopoietic cell transplant patients

Single-cell multiomics reveals molecular identities and clonal dynamics of MRD progression in Myelodysplastic Syndromes after stem cell transplant

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial

Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

A Multicenter Analysis of Allogeneic Transplant Outcomes in Patients with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Clinical Factors Associated with Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation

The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only